# A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC

Source: https://onco.cc/trials/nct05844150/  
OnCo record `nct05844150` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of PM8002 and Etoposide in small-cell lung cancer, run by Biotheus Inc., active and no longer recruiting.

## Summary

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC is a phase 2 interventional study registered as NCT05844150 by Biotheus Inc., with 50 participants enrolled, started 2023-06-01 and due to reach its primary completion in 2024-05-10. Interventions recorded: PM8002, Platinum and Etoposide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05844150
- Phase: 2
- Setting: A Phase II Clinical Trial to Evaluate the Efficacy and Safety of PM8002 in Combination With Etoposide and Platinum in First-line Treatment of Extensive-Stage Small Cell Lung Cancer
- Sponsor: Biotheus Inc.
- Enrolled: 50

## Sources

- ClinicalTrials.gov NCT05844150: https://clinicaltrials.gov/study/NCT05844150

## Connected records

- cancers: [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Etoposide](https://onco.cc/drugs/etoposide/), [PM8002](https://onco.cc/drugs/pm8002/)
- companies: [BioNTech](https://onco.cc/companies/biontech/)

---
JSON: https://onco.cc/api/v1/entities/nct05844150.json